Fund III
1 known investors
VERIGRAFT develops technology that modifies donated tissue so it resembles a patient's own tissue, aiming to eliminate immune rejection in transplantation and reduce the need for lifelong immunosuppressants. The company targets patients requiring tissue or organ transplants and addresses currently incurable diseases.
BiotechHealthtechMedical Devices
Founders & leadership
PB
Petter BjörquistPhD, Chief Executive Officer